Overview
Effects of ONO-2506PO in Patients With Alzheimer's Disease
Status:
Completed
Completed
Trial end date:
2007-07-01
2007-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ono Pharma USA Inc
Criteria
Inclusion Criteria:- Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
- Standardized MMSE Score of 13 to 24 points (inclusive)
- Modified Hachinski score equal or less than 4
Exclusion Criteria:
- Serious systemic disease that may preclude survival to study completion
- Other illnesses that may include dementive features